<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1101221583
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KANUMA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SEBELIPASE ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32606.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Italia S.P.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Italia S.P.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alexion Europe SAS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AB14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>KANUMA contains the active substance sebelipase alfa. Sebelipase alfa is similar to the naturally occurring enzyme lysosomal acid lipase (LAL), which the body uses to breakdown fats. It is used to treat patients of all ages with lysosomal acid lipase deficiency (LAL deficiency).<br />LAL deficiency is a genetic disease that leads to liver damage, high blood cholesterol, and other complications due to a build-up of certain types of fats (cholesteryl esters and triglycerides).<br />How KANUMA works<br />This medicine is an enzyme replacement therapy. This means that it replaces the missing or defective LAL enzyme in patients with LAL deficiency. This medicine works by lowering the build-up of fat that causes medical complications, including impaired growth, liver damage and heart complications. It also improves blood levels of fats, including elevated LDL (bad cholesterol) and triglycerides.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must not be given KANUMA</p><p>- If you or your child has experienced life-threatening allergic reactions to sebelipase alfa that cannot be managed when you or your child receives the medicine again, or to egg or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>Warnings and precautions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If treated with KANUMA, you or your child may experience a side effect while you or your child is being given the medicine or during the hours following the infusion (see section 4). This is known as an infusion reaction which can sometimes be severe, and may include an allergic reaction that could be life-threatening and require medical treatment. The first time that you or your child are given KANUMA you should be observed by a healthcare professional for 1 hour to watch for any signs of an infusion reaction. <strong>If you or your child experiences a severe infusion reaction like this, seek immediate medical attention</strong>. If you or your child has an infusion reaction you or your child may be given additional medicines to treat or help prevent future reactions. These medicines may include antihistamines, fever-reducing medicines and/or corticosteroids (a type of anti-inflammatory medicines).</p><p>If the infusion reaction is severe, your doctor may stop KANUMA infusion and start giving you or your child appropriate medical treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine may contain egg proteins. If you or your child has an egg allergy or a history of allergies to eggs, tell your doctor or nurse (see <strong>You must not be given KANUMA</strong>).&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and KANUMA</strong></p><p>Tell your doctor if you or your child are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p>Pregnancy&nbsp;</p><p>There are no data from the use of sebelipase alfa in pregnant women. As a precautionary measure, you should not be given KANUMA if you are pregnant.&nbsp;</p><p>&nbsp;</p><p>Breast-feeding</p><p>It is not known whether sebelipase alfa passes into breast milk. Tell your doctor if you are breastfeeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, or whether to stop taking KANUMA, considering the benefit of breast-feeding to the baby and the benefit of KANUMA to the mother.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>KANUMA has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>KANUMA contains sodium&nbsp;</p><p>This medicine, when diluted with sodium chloride 9 mg/mL (0.9%) solution for injection for intravenous administration contains 33 mg sodium (main component of cooking/table salt) at the recommended dose. This is equivalent to 1.7% of the recommended maximum daily dietary intake of sodium for an adult. Tell your doctor if you or your child is on a controlled sodium diet.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The dose you or your child receives is based on your or your child&rsquo;s body weight.</p><p>&nbsp;</p><p>Infants (&lt; 6 months of age)</p><p>For patients who have signs and symptoms of the disease when they are infants, the recommended starting dose is 1 mg/kg once weekly. Dose adjustments may be considered based on how well you or your child responds to treatment.&nbsp;</p><p>&nbsp;</p><p>Children and adults</p><p>The recommended dose is 1 mg per kg body weight once every other week through a drip into a vein.</p><p>&nbsp;</p><p>Each infusion will take approximately 1 to 2 hours. You or your child may be monitored by your doctor or nurse for an additional hour after the infusion. KANUMA should be started at as young an age as possible and is intended for long-term use.</p><p>&nbsp;</p><p>Your doctor or nurse will give KANUMA to you or your child by an infusion (drip) into a vein. The medicine will be diluted before being given to you or your child.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Side effects were seen while patients were being given the medicine or shortly after (infusion reactions). The most serious side effects may include an allergic reaction (seen very commonly [may affect more than 1 in 10 people] in infants younger than 6 months old, or commonly [may affect up to 1 in 10 people] in children and adults) with symptoms including difficulty breathing, swelling of the throat, rapid breathing, fast heartbeat, chest discomfort, mild swelling of eyelids, red eyes, runny nose, flushing, and hives. <strong>If you or your child experiences symptoms like these, seek immediate medical attention.</strong> If you or your child has an infusion reaction you or your child may be given additional medicines to treat or help prevent future reactions. If the infusion reaction is severe, your doctor may stop the infusion of KANUMA in the vein and start giving appropriate medical treatment.</p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10 people) side effects reported in infants (1 to 6 months old) are:&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:602px"><tbody><tr><td style="vertical-align:top"><p>eyelid swelling</p></td><td style="vertical-align:top"><p>agitation</p></td><td style="vertical-align:top"><p>high blood pressure</p></td></tr><tr><td style="vertical-align:top"><p>decreased muscle tone&nbsp;</p></td><td style="vertical-align:top"><p>difficulty breathing</p></td><td style="vertical-align:top"><p>wheezing</p></td></tr><tr><td style="vertical-align:top"><p>paleness</p></td><td style="vertical-align:top"><p>stuffy or swollen nose</p></td><td style="vertical-align:top"><p>sneezing</p></td></tr><tr><td style="vertical-align:top"><p>cough&nbsp;</p></td><td style="vertical-align:top"><p>heartburn (reflux diseases)</p></td><td style="vertical-align:top"><p>dry heaving</p></td></tr><tr><td style="vertical-align:top"><p>diarrhoea&nbsp;</p></td><td style="vertical-align:top"><p>hives</p></td><td style="vertical-align:top"><p>rash</p></td></tr><tr><td style="vertical-align:top"><p>vomiting&nbsp;</p></td><td style="vertical-align:top"><p>itching</p></td><td style="vertical-align:top"><p>raised rash</p></td></tr><tr><td style="vertical-align:top"><p>red swollen skin</p></td><td style="vertical-align:top"><p>fever</p></td><td style="vertical-align:top"><p>swelling</p></td></tr><tr><td style="vertical-align:top"><p>chills&nbsp;</p></td><td style="vertical-align:top"><p>rapid breathing</p></td><td style="vertical-align:top"><p>decreased oxygen in the blood&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>fast heartbeat</p></td><td style="vertical-align:top"><p>irritability</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people) side effects reported in children and adolescents (4 to 18 years old) and adults are:&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:602px"><tbody><tr><td style="vertical-align:top"><p>severe allergic reaction (anaphylactic reaction)</p></td><td style="vertical-align:top"><p>infection of the urinary system</p></td><td style="vertical-align:top"><p>swelling of the eyelids</p></td></tr><tr><td style="vertical-align:top"><p>temporary increased</p><p>cholesterol or triglyceride (fats) levels in the blood</p></td><td style="vertical-align:top"><p>fast heartbeat</p></td><td style="vertical-align:top"><p>anxiety</p></td></tr><tr><td style="vertical-align:top"><p>Sleeplessness</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>low blood pressure</p></td></tr><tr><td style="vertical-align:top"><p>redness in face</p></td><td style="vertical-align:top"><p>shortness of breath</p></td><td style="vertical-align:top"><p>swelling of the throat</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>stomach ache</p></td><td style="vertical-align:top"><p>stomach bloating</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Hives</p></td><td style="vertical-align:top"><p>rash</p></td></tr><tr><td style="vertical-align:top"><p>Itching</p></td><td style="vertical-align:top"><p>red swollen skin</p></td><td style="vertical-align:top"><p>increased menstrual bleeding</p></td></tr><tr><td style="vertical-align:top"><p>Shivers</p></td><td style="vertical-align:top"><p>chest discomfort</p></td><td style="vertical-align:top"><p>swelling</p></td></tr><tr><td style="vertical-align:top"><p>Tiredness</p></td><td style="vertical-align:top"><p>hardened area around the infusion site</p></td><td style="vertical-align:top"><p>fever</p></td></tr></tbody></table><p>&nbsp;</p><p>Frequency, type and severity of adverse reactions in children are the same as in adults.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2 &deg;C to 8 &deg;C). Do not freeze. Do not shake. Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For diluted solutions, immediate use is recommended. If not used immediately, the diluted solution may be stored up to 24 hours at 2 &deg;C to 8 &deg;C or up to 12 hours below 25 &deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.<em> </em></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is sebelipase alfa. Each ml of concentrate contains 2 mg sebelipase alfa. Each vial contains 20 mg of sebelipase alfa in 10 ml.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are sodium citrate (see section 2 under &lsquo;KANUMA contains sodium&rsquo;), citric acid monohydrate, human serum albumin, and water for injections.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                KANUMA is supplied as a concentrate for solution for infusion (sterile concentrate). It is a solution that is clear to slightly opalescent, and colourless to slightly coloured.  
 
Pack size: 1 vial containing 10 ml of concentrate. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorisation Holder</u></p><p>Alexion Europe SAS</p><p>103-105 rue Anatole France</p><p>92300 Levallois-Perret</p><p>France</p><p>&nbsp;</p><p><u>Manufacturer:</u></p><p>Almac Pharma Services</p><p>Seagoe Industrial Estate</p><p>Craigavon BT63 5UA</p><p>United Kingdom</p><p>&nbsp;</p><p>Alexion Pharma International Operations Unlimited Company</p><p>College Business and Technology Park</p><p>Blanchardstown</p><p>Dublin 15</p><p>Ireland</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                  April 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كانوما على المادة الفعالة سيبيلايبيز ألفا. سيبيلايبيز ألفا يُشبه الإنزيم الطبيعي المُسمّى اللايبيزالحمضي الليزوزومي )LAL(، والذي يستخدمه الجسم لتحطيم الدهون.&nbsp; يُستخدم سيبيلايبيز ألفا في علاج المرضى من جميع الأعمار ممن يعانون من نقص إنزيم اللايبيز الحمضي الليزوزومي )نقص LAL(.<strong> </strong></p><p dir="RTL">&nbsp;نقص LAL هو مرض وراثي يؤدي إلى تلف الكبد وارتفاع الكوليسترول في الدم وغير ذلك من المضاعفات الناجمة عن تراكم أنواع معينة من الدهون )الإسترات الكوليسترولية والدهو ن الثلاثية.( <strong>ألية عمل كانوما &nbsp;</strong></p><p dir="RTL">هذا الدواء هو علاج بديل للإنزيم . وهذا يعني أنه يعوض عن إنزيم LAL الناقص أو المعطوب لدى المرضى الذين يعانون من نقص إنزيم LAL. وهو يعمل عن طريق خفض تراكم الدهو ن التي تسبب مضاعفات</p><p dir="RTL">صحية، بما في ذلك ضعف النمو وتلف الكبد ومضاعفات في القلب. كما أنه يحسن مستويات الدهون في الدم، بما في ذلك المستويات المرتفعة من البروتين الدهني منخفض الكثافة &quot;LDL&quot; )الكوليسترول السيئ( والدهون الثلاثية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب ألا تتلقى العلاج بكانوما :&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت أنت أو طفلك من ردود فعل تحسسية مهددة للحياة نحو سيبيلايبيز ألفا والتي لا يمكن تفاديها إذا تلقيت أنت أو طفلك الدواء مرة أخرى، أو للب&nbsp; يض أو لأي من المكونات الأخرى لهذا الدواء</p><p dir="RTL">)المذكورة في الفقرة رقم 6(.</p><p dir="RTL"><strong>التحذيرات والإحتياطات </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عولجت بـكانوما أنت أو طفلك فقديواجه أي منكما أعراضًا جانبية أثناء تلقي العلاج أو خلال&nbsp;&nbsp;&nbsp; الساعات التالية للحقن الوريدي)انظر الفقرة رقم 4(.</p><p dir="RTL">يعرف هذا باسم رد فعل ناجم عن الحقن الوريدي وقد يكون في بعض الأحيان شديدً ا، ويمكن أن يشمل رد فعل تحسسي يمكن أن يهدد الحياة ويتطلب علاجًا طبيا. في المرة الأولى التي تحصل فيها أنت أو طفلك على كانوما، يجب أن تتم ملاحظتك من قبل أخصائي الرعاية الصحية لمدة ساعة واحدة لمراقبة أي علامات &nbsp;لرد فعل الحقن.</p><p dir="RTL">&nbsp;. <strong>إذا تعرضت أنت أو طفلك لرد فعل شديد ناجم عن الحقن، فاطلب عناية طبية فورية</strong>. إذا تعرضت أنت أو</p><p dir="RTL">طفلك لرد فعل ناجم عن الحقن، فقد يتم إعطاؤك أنت أو طفلك أدوية إضافية لعلاج أو للمساعدة في منع ردود الفعل المستقبلية. قد تشمل هذه الأدوية مضادات الهيستامين والأدوية التي تقلل الحمى و/أو الكورتيكوستيرويدات )نوع من الأدوية المضادة للالتهابات(.</p><p dir="RTL">إذا كان رد الفعل الناجم عن الحقن شديدًا، فقد يقوم طبيبك بإيقاف الحقن ويبدأ في إعطائك أو إعطاء طفلك العلاج الطبي المناسب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتوي هذا الدواء على بروتينات البيض. إذا كنت أنت أو طفلك مصابا بحساسية نحو البيض أو لديك&nbsp;&nbsp;&nbsp;&nbsp; تاريخًا من الحساسية نحو البيض، فأخبر طبيبك أو ممرضك) أنظر &quot;يجب ألا تتلقى العلاج بكانوما&quot;(.</p><p dir="RTL"><strong>الأدوية الأخرى&nbsp; وكانوما&nbsp; </strong></p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم أنت أو طفلك، أو استخدمتما مؤخراً أو قد تستخدما أي أدوية أخرى.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل&nbsp; </strong></p><p dir="RTL">لا توجد بيانات حول استخدام <u>سيبيلايبيز</u> ألفا في النساء الحوامل. كإجراء احترازي ، لا يجب أن تعطى كانوما&nbsp; إذا كنت حاملاً <strong>الرضاعة الطبيعية </strong></p><p dir="RTL">من غير المعروف ما إذا كان سيبيلايبيز ألفا ينتقل إلى حليب الأم. أخبري طبيبك إذا كنت مرضعة أو تخططين للقيام بذلك. سيساعدك طبيبك بعد ذلك على تحديد ما إذا كنت ستتوقفين عن الرضاعة الطبيعية، أو ما إذا كنت ستتوقفين عن تناول كانوما، مع الأخذ في الإعتبار فائدة الرضاعة الطبيعية للطفل و فائدة كانوما للأم&nbsp; .&nbsp;</p><p dir="RTL">إذا كنت حاملاً أو م رضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل ، استشيري طبيبك قبل تناول هذا &nbsp;الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">ليس لدى كانوما أي تأثير أو أنّ&nbsp; له تأثير لا يذكر على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL"><strong>كانوما يحتوي على الصوديوم </strong></p><p dir="RTL">&nbsp;هذا الدواء ، عند تخفيفه باستخدام كلوريد الصوديوم 9 مجم / مل) 0.9٪( محلول للحقن عن طريق الوريد يحتوي على 33 مجم صوديوم )المكون الرئيسي للطبخ / ملح الطعام( بالجرعة الموصى بها. هذا يعادل</p><p dir="RTL"><sub>&nbsp;</sub>1.7٪ من الحد الأقصى الموصى به من المدخول الغذائي اليومي من الصوديوم للشخص البالغ.</p><p dir="RTL">أخبر طبيبك إذا كنت أنت أو طفلك تتبعان حمية عن الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تعتمد الجرعة التي تتلقاها أنت أو طفلك على وزن جسمك أو جسم طفلك.</p><p dir="RTL">&nbsp;<strong>ا الرضّع&nbsp; )أقل من </strong><strong>6</strong><strong> أشهر من العمر( </strong></p><p dir="RTL">تبلغ جرعة البداية للمرضى الذين تظهر عليهم أعراض المرض&nbsp; وهم رضّع 1 مجم/كجم مرة واحدة في الأسبوع. قد يأخذ الطبيب في عين الاعتبار إدخال تعديلات على الجرعة بناءً على مدى استجابتك للعلاج أنت أو طفلك.&nbsp;</p><p dir="RTL"><strong>الأطفال و الكبار&nbsp; </strong></p><p dir="RTL">الجرعة الموصى بها هي 1 مجم لكل كجم من وزن الجسم مرة كل أسبوعين عن طريق التنقيط في الوريد.</p><p dir="RTL">ستستغرق كل حقنة حوالي ساعة إلى ساعتين .قد تتم مراقبتك أنت أو طفلك من قبل طبيبك أو ممرضتك</p><p dir="RTL">لمدة ساعة إضافية بعد الحقن. يجب أن تبدأ كانوما في سن مبكرة قدر الإمكان و هي مخصصة للإستخدام على المدى الطويل.</p><p dir="RTL">سيقوم طبيبك أو الممرض بإعطاء كانوما لك أو لطفلك عن طريق الحقن )بالتنقيط( في الوريد. سيتم تخفيف الدواء قبل إعطائه لك أو لطفلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، على الرغم من أنها لا تحدث لدى جميع من يتلقاه .</p><p dir="RTL">لوحظ حدوث الأعراض الجانبية أثناء حقن المرضى بالدواء أو بعد فترة وجيزة) رد فعل للحقن(.&nbsp; قد تشمل الأعراض الجانبية الأكثر خطورة رد فعل تحسسي) يحدث بشكل شائع جدًا ]قد يؤثر على أكثر من 1 من كل 10 أشخاص[ لدى الرضّع الذين تقل أعمارهم عن 6 أشهر، أو بشكل شائع ]قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص[ لدى الأطفال والبالغين( مع أعراض تشمل صعوبة في التنفس وتورم في الحلق ،والتنفس السريع ،وتسارع ضربات القلب ، وألم في الصدر ، وتورم خفيف في الجفون،&nbsp; واحمرار العينين،</p><p dir="RTL">&nbsp;وسيلان الأنف،&nbsp; واحمرار الوجه،&nbsp; والشرى. <strong>إذا عانيت أنت أو طفلك من أعراض مثل هذه، فاطلب الرعاية </strong></p><p dir="RTL"><strong>الطبية الفورية.</strong> إذا تعرّضت أنت أو طفلك لرد فعل ناجم عن الحقن، فقد يتم إعطاؤك أنت أو طفلك أدوية إضافية لعلاج أو للمساعدة في منع ردود الفعل في المستقبل. إذا كان رد الفعل الناجم عن الحقن لديك شديد اً،&nbsp; قد يلجأ الطبيب لإيقاف حقن كانوما في الوريد والبدء في إعطاء العلاج الطبي المناسب.</p><p dir="RTL">الأعراض الجانبية الشائعة جدًا )قد تظهر لدى أكثر من 1من كل 10 أشخاص( المُبلغ عنها لدى الرضع )من عمر 1 إلى 6 أشهر( هي:</p><table border="0" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">ارتفاع ضغط الدم</p></td><td style="vertical-align:top"><p dir="RTL">انفعال</p></td><td style="vertical-align:top"><p dir="RTL">تورّم الجفن.</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">صفير</p></td><td style="vertical-align:top"><p dir="RTL">صعوبة التنفس</p></td><td style="vertical-align:top"><p dir="RTL">تدني قوة العضلات</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عطاس</p></td><td style="vertical-align:top"><p dir="RTL">احتقان أو تورّم الأنف</p></td><td style="vertical-align:top"><p dir="RTL">شحوب</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;التهوع أو محاولة التقيؤ</p></td><td style="vertical-align:top"><p dir="RTL">حرقة المعدة )الارتجاع المَعِدي المَريئي(</p></td><td style="vertical-align:top"><p dir="RTL">سعال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">طفح</p></td><td style="vertical-align:top"><p dir="RTL">شرى</p></td><td style="vertical-align:top"><p dir="RTL">إسهال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">طفح مرتفع</p></td><td style="vertical-align:top"><p dir="RTL">حكّة</p></td><td style="vertical-align:top"><p dir="RTL">قيء</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تورم</p></td><td style="vertical-align:top"><p dir="RTL">حمى</p></td><td style="vertical-align:top"><p dir="RTL">احمرار وتورم الجلد</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">نقص الأكسجين في الدم</p></td><td style="vertical-align:top"><p dir="RTL">تنفس سريع</p></td><td style="vertical-align:top"><p dir="RTL">قشعريرة</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">هيجان</p></td><td style="vertical-align:top"><p dir="RTL">تسارع ضربات القلب</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">الأعراض الجانبية الشائعة )قد تظهر لدى ما يصل إلى 1من كل 10 أشخاص(&nbsp; المُ ب لغ عنها لدى الأطفال والمراهقين )من 4 إلى 18 عامًا( والبالغين هي:</p><table border="0" cellspacing="0" cellpadding="0" style="width:643px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">تورّم الجفو ن</p></td><td style="vertical-align:top"><p dir="RTL">التهاب مجرى البول</p></td><td style="vertical-align:top"><p dir="RTL">رد فعل تحسسي شديد )التأق(</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قلق</p></td><td style="vertical-align:top"><p dir="RTL">تسارع ضربات القلب</p></td><td style="vertical-align:top"><p dir="RTL">ارتفاع مؤقت في مستوى الكولسترول أو الدهون الثلاثية )الدهون( في الدم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض ضغط الدم</p></td><td style="vertical-align:top"><p dir="RTL">دوخة</p></td><td style="vertical-align:top"><p dir="RTL">الأر ق</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تورم الحلق</p></td><td style="vertical-align:top"><p dir="RTL">ضيق التنفس</p></td><td style="vertical-align:top"><p dir="RTL">احمرار الوجه</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">غازات البطن</p></td><td style="vertical-align:top"><p dir="RTL">ألم في المعدة</p></td><td style="vertical-align:top"><p dir="RTL">اسهال</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">طفح</p></td><td style="vertical-align:top"><p dir="RTL">شرى</p></td><td style="vertical-align:top"><p dir="RTL">غثيان&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">زيادة نزيف الحيض</p></td><td style="vertical-align:top"><p dir="RTL">احمرار وتورم الجلد</p></td><td style="vertical-align:top"><p dir="RTL">حكّة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تورّم</p></td><td style="vertical-align:top"><p dir="RTL">شعور بالضيق في الصدر</p></td><td style="vertical-align:top"><p dir="RTL">ارتجاف</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">حرارة</p></td><td style="vertical-align:top"><p dir="RTL">تيبّس حول موضع الحقن</p></td><td style="vertical-align:top"><p dir="RTL">التعب</p></td></tr></tbody></table><p dir="RTL">هناك تشابه في تواتر ونوع وشدة ردود الفعل السلبية بين الأطفال&nbsp; والبالغين.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور في الملصق والكرتون بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يُحفظ في الثلاجة) 2 - 8 درجة مئوية(. لا تجمده. لا ترجّه. يُحفظ داخل العلبة الأصلية من أجل حمايته من الضوء.</p><p dir="RTL">يوصى باستخدام المحاليل المُ خ ففة على الفور .إذا لم تستخدم على الفور، فإنه يمكنك حفظها لمدة تصل إلى 24 ساعة في درجة حرارة تتراوح بين 2 - 8 درجة مئوية أو إلى ما يصل إلى 12 ساعة عند حفظها في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp; المادة الفعالة هي سيبيلايبيز ألفا. يحتوي كل مل من المُ ركّ ز على 2 مجم سيبيلايبيز ألفا. تحتوي كل&nbsp;&nbsp;&nbsp;&nbsp; قارورة على 20 مجم من سيبيلايبيز ألفا في 10 مل.</p><p dir="RTL">-&nbsp;&nbsp; المكونات الأخرى هي سترات الصوديم )انظر الفقرة 2 تحت &quot;كانوما يحتوي على الصوديوم&quot;(، مونوهيد ارت حامض الستريك ، ألبيومين مصل الدّم البشري والماء المُخصّص للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفّر كانوما على شكل مُركّز لتحضير محلول للحقن الوريدي )تركيز معقم(. وهو عبارة عن محلول صافي أو غائم قليلًا، وعديم اللون أو له لون خفيف.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;حجم العبوة: قارورة واحدة تحتوي على 10 مل من المُ ركز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> رخصة التسويق والمُصنّع </strong></p><p dir="RTL"><strong>مالك</strong><u> رخصة التسويق</u> أليكسيون أوروبا ساس</p><p dir="RTL">103-105 شارع أناتول فرنسا</p><p dir="RTL">92300 ليفالوا بيريه فرنسا</p><p dir="RTL"><u>المُصنع</u></p><p dir="RTL">ألماك فارما للخدمات منطقة سيغو الصناعية كريجافون BT63 5UA المملكة المتحدة</p><p dir="RTL">شركة أليكسون فارما الدولية للعمليات غير المحدودة كلية الأعمال والتكنولوجيا بارك</p><p dir="RTL">بلانتشارستاو ن</p><p dir="RTL">دبلن 15 أيرلندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
              نيسان ٢٠٢٢
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                KANUMA 2 mg/ml concentrate for solution for infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of concentrate contains 2 mg sebelipase alfa*. 
Each vial of 10 ml contains 20 mg sebelipase alfa. 
* produced in egg white of transgenic Gallus by recombinant DNA (rDNA) technology. 
 
Excipient with known  effect Each vial contains 33 mg sodium. 
 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate). 
 
Clear to slightly opalescent, colourless to slightly coloured solution. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>KANUMA is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>KANUMA treatment should be supervised by a healthcare professional experienced in the management of patients with LAL deficiency, other metabolic disorders, or chronic liver diseases. KANUMA should be administered by a trained healthcare professional who can manage medical emergencies.</p><p>&nbsp;</p><p>Posology</p><p>&nbsp;</p><p>It is important to initiate treatment as early as possible after diagnosis of LAL deficiency.</p><p>&nbsp;</p><p>For instructions on the preventive measures and monitoring of hypersensitivity reactions, see section 4.4. Following the occurrence of a hypersensitivity reaction, appropriate pre-treatment should be considered according to the standard of care (see section 4.4).</p><p><em>Patients with Rapidly Progressive LAL Deficiency Presenting within the First 6 Months of Life </em></p><p>The recommended starting dose in infants (&lt; 6 months of age) presenting with rapidly progressive LAL deficiency is either 1 mg/kg or 3 mg/kg administered as an intravenous infusion once weekly, depending on the clinical status of the patient. A higher starting dose of 3 mg/kg should be considered based on the severity of the disease and rapid disease progression.</p><p>&nbsp;</p><p>&nbsp;</p><p>Dose escalations should be considered based on suboptimal response to clinical and biochemical criteria, including, e.g., poor growth (especially mid-upper arm circumference, MUAC), deteriorating biochemical markers (e.g. liver transaminases, ferritin, C-reactive Protein, and coagulation parameters), persistent or worsening organomegaly, increased frequency of intercurrent infections, and persistent worsening of other symptoms (e.g. gastrointestinal symptoms):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a dose escalation to 3 mg/kg should be considered in case of suboptimal clinical response;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a further dose escalation up to 5 mg/kg should be considered in case of persistent suboptimal clinical response.</p><p>Further dose adjustments, as a reduction of the dose or an extension of the dose interval, can be made on an individual basis based on achievement and maintenance of therapeutic goals. Clinical studies evaluated doses ranging from 0.35 to 5 mg/kg once weekly, with one patient receiving a higher&nbsp; dose of 7.5 mg/kg once weekly. Doses higher than 7.5 mg/kg have not been studied.</p><p>&nbsp;</p><p><em>Pediatric and Adult Patients with LAL Deficiency </em></p><p>The recommended dose in children and adults who do not present with rapidly progressive LAL deficiency prior to 6 months of age is 1 mg/kg administered as an intravenous infusion once every other week. Dose escalation to 3 mg/kg once every other week should be considered based on suboptimal response to clinical biochemical criteria, including; e.g., poor growth persistent or deteriorating biochemical markers (e.g., parameters of liver injury (ALT, AST), parameters of lipid metabolism (TC, LDL-c, HDL-c, TG), persistent or worsening organomegaly, and persistent worsening of other symptoms (e.g., gastrointestinal symptoms).</p><p>&nbsp;</p><p><em><u>Special populations</u></em><em> </em></p><p><em>&nbsp;</em></p><p>Renal impairment</p><p>No dosing adjustment is recommended in patients with renal impairment based on current knowledge of the pharmacokinetics and pharmacodynamics of sebelipase alfa (see section 5.2).</p><p>&nbsp;</p><p>Hepatic impairment</p><p>No dosing adjustment is recommended in patients with hepatic impairment based on current knowledge of the pharmacokinetics and pharmacodynamics of sebelipase alfa (see section 5.2).</p><p>&nbsp;</p><p>Elderly population ( 65 years old)</p><p>The safety and efficacy of sebelipase alfa in patients older than 65 years have not been evaluated and no alternative dose regimens can be recommended for these patients (see section 5.1).</p><p>&nbsp;</p><p>Overweight patients</p><p>The safety and efficacy of sebelipase alfa in overweight patients have not been thoroughly evaluated and therefore no alternative dose regimens can be recommended for these patients at this time.</p><p>&nbsp;</p><p>Paediatric population</p><p>Administration of sebelipase alfa to infants with confirmed multiple-organ failure should be at the discretion of the treating physician.</p><p>&nbsp;</p><p>Method of administration</p><p>&nbsp;</p><p>KANUMA is for intravenous (IV) use only.</p><p>The total volume of the infusion should be administered over approximately 2 hours. A 1-hour infusion may be considered after patient tolerability is established. The infusion period may be extended in the event of dose escalation.</p><p>&nbsp;</p><p>KANUMA should be administered through a 0.2 &mu;m filter (see section 6.6).</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Life-threatening hypersensitivity (anaphylactic reaction) to the active substance when attempts to rechallenge are unsuccessful, or to egg or any of the excipients listed in section 6.1, (see section 4.4). 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability</p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>Hypersensitivity reactions including anaphylaxis</p><p>&nbsp;</p><p>Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with sebelipase alfa; see section 4.8. Therefore, appropriate medical support must be readily available when sebelipase alfa is administered. If severe reactions occur, the sebelipase alfa infusion should be immediately stopped and appropriate medical treatment should be initiated. The risks and benefits of re-administering sebelipase alfa following a severe reaction should be considered.</p><p>&nbsp;</p><p>Following the first sebelipase alfa infusion, including the first infusion after a dose escalation, patients should be observed for 1 hour in order to monitor for any signs or symptoms of anaphylaxis or a severe hypersensitivity reaction.</p><p>&nbsp;</p><p>The management of hypersensitivity reactions may include temporarily interrupting the infusion, lowering the infusion rate, and/or treatment with antihistamines, antipyretics, and/or corticosteroids. For patients who have experienced allergic reactions during infusion, caution should be exercised upon re-administration. If interrupted, the infusion may be resumed at a slower rate with increases as tolerated. Pre-treatment with antipyretics and/or antihistamines may prevent subsequent reactions in those cases where symptomatic treatment was required.</p><p>&nbsp;</p><p>In cases of severe infusion reactions and in cases of lack or loss of effect, patients should be tested for the presence of antibodies.</p><p>&nbsp;</p><p>This medicinal product may contain traces of egg proteins. Patients with known egg allergies were excluded from clinical studies (see section 4.3).</p><p>&nbsp;</p><p>Immunogenicity</p><p>&nbsp;</p><p>As with all therapeutic proteins, there is potential for immunogenicity. In the sebelipase alfa clinical program, patients were routinely tested for anti-sebelipase alfa anti-drug antibodies (ADAs) to determine the immunogenicity potential of sebelipase alfa. Patients who tested positive for ADAs were also tested for inhibitory antibody activity. The presence of inhibitory activity has been detected at some postbaseline timepoints in clinical studies (see section 4.8). Overall, no conclusion on the relationship between development of ADAs/NAbs and associated hypersensitivity reactions or suboptimal clinical response can be made.</p><p>In clinical studies, 3 patients homozygous for a deletion affecting both alleles of genes Lipase A, lysosomal acid [LIPA] and Cholesterol 25-Hydroxylase developed inhibitory antibody activity associated with a suboptimal clinical response. These patients underwent either immunomodulatory therapy alone or in combination with haematopoietic stem cell transplant (HSCT) or bone marrow transplant (BMT), resulting in improved clinical response to sebelipase alfa.</p><p>&nbsp;</p><p>Excipients</p><p>&nbsp;</p><p>This medicinal product contains 33 mg sodium per vial equivalent to 1.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult. It is administered&nbsp; in&nbsp; sodium chloride 9&nbsp; mg/ml (0.9%) solution for infusion (see section 6.6). This should be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>Because it is a recombinant human protein, sebelipase alfa is an unlikely candidate for cytochrome P450 mediated or other drug-drug interactions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>&nbsp;</p><p>There are no or limited data from the use of sebelipase alfa in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid use of sebelipase alfa during pregnancy.</p><p>&nbsp;</p><p>Breast-feeding</p><p>&nbsp;</p><p>There are no data from studies in breast-feeding women. It is not known whether sebelipase alfa is excreted in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from sebelipase alfa therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p>Fertility</p><p>&nbsp;</p><p>There are no clinical data on the effects of sebelipase alfa on fertility. Animal studies show no evidence of impaired fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>KANUMA may have a minor influence on the ability to drive and use machines. Adverse events of dizziness have been reported with the use of sebelipase alfa, which could affect the ability to drive or use machines (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile</p><p>&nbsp;</p><p>The data described below reflect the exposure to sebelipase alfa in 125 patients at doses ranging from 0.35 mg/kg once every other week to 7.5 mg/kg once weekly in clinical studies (see section 5.1), with a treatment duration range from 1 day to 60.5 months (5 years).</p><p>Of the 106 children and adults enrolled&nbsp; in&nbsp; clinical&nbsp; studies, 102 (96.2%) have received sebelipase alfa at a dosage regimen of 1 mg/kg once every other week, with a median duration of exposure of 33 months (6, 59 months). The median duration of exposure for the 19 infants enrolled in clinical studies was 35.5 months (1 day to 60 months).</p><p>&nbsp;</p><p>The most serious adverse reactions experienced by 4% of patients in clinical studies were signs and symptoms consistent with anaphylaxis. Signs and symptoms included chest discomfort, conjunctival hyperaemia, dyspnoea, hyperaemia, eyelid oedema, rhinorrhoea, severe respiratory distress, tachycardia, tachypnoea, irritability, flushing, pruritus, urticaria, stridor, hypoxia, pallor and&nbsp; diarrhoea.</p><p>&nbsp;</p><p>Tabulated list of adverse reactions</p><p>&nbsp;</p><p>The data in Table 1 describe adverse reactions reported in infants who received sebelipase alfa in clinical studies. The data in Table 2 describe adverse reactions reported in children and adults who received sebelipase alfa in clinical studies.</p><p>&nbsp;</p><p>Adverse reactions are listed by system organ class (SOC) and frequency. Frequencies are defined according to the following convention: very common ( 1/10); common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p>Table 1: Adverse reactions reported in infants receiving sebelipase alfa (N = 19 patients)</p><table border="0" cellspacing="0" cellpadding="0" style="width:599px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System organ class </strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Preferred Term </strong></p></td><td style="vertical-align:top"><p><strong>Frequency </strong></p></td></tr><tr><td><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>a</sup><sub> </sub></p><p>Anaphylactic reaction<sup>b</sup><sub> </sub></p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Eye Disorders</p></td><td style="vertical-align:top"><p>Eyelid oedema</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Respiratory distress</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Vomiting Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p><p>Rash maculo-papular</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Hyperthermia</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Investigations</p></td><td style="vertical-align:top"><p>Drug specific antibody present</p><p>Body temperature increased</p><p>Oxygen saturation decreased</p><p>Blood pressure increased</p><p>Heart rate increased</p><p>Respiratory rate increased</p></td><td style="vertical-align:top"><p>Very common</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>May include: irritability, agitation, vomiting, urticaria, eczema, pruritus, pallor, and drug hypersensitivity</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Occurred in 3 infant patients treated in clinical studies. Based on Preferred Term &lsquo;anaphylactic reaction&rsquo; and application of Sampson criteria to identify signs/symptoms consistent with anaphylaxis.</p><p>&nbsp;</p><p>Table 2: Adverse reactions reported in children and adults receiving sebelipase alfa (N = 106 patients)</p><table border="0" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System organ class </strong></p></td><td style="vertical-align:top"><p><strong>MedDRA preferred term </strong></p></td><td style="vertical-align:top"><p><strong>Frequency </strong></p></td></tr><tr><td rowspan="2"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>b</sup><sub> </sub></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction<sup>a</sup><sub> </sub></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hyperaemia Hypotension</p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Dyspnoea</p></td><td><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain Diarrhoea</p></td><td><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p><p>Rash papular</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue Pyrexia</p></td><td><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Chest discomfort</p><p>Infusion site reaction<sup>c</sup><sub> </sub></p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Body temperature increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><sup>a&nbsp; </sup>Occurred in 2 patients treated in clinical studies. Based on Preferred Term &lsquo;anaphylactic reaction&rsquo; and application of Sampson criteria to identify signs/symptoms consistent with anaphylaxis.</p><p><sup>b </sup>May include: chills, eczema, laryngeal oedema, nausea, pruritus, urticaria. <sup>c </sup>Includes: infusion site extravasation, infusion site pain and infusion site urticaria</p><p>Description of selected adverse reactions</p><p><em>Hypersensitivity </em></p><p>Five of 125 (4%) patients treated with sebelipase alfa, including 3 of 19 (16%) infants and 2 of 106 (2%) children and adults, in clinical studies experienced serious signs and symptoms consistent with anaphylaxis to sebelipase alfa. Anaphylaxis occurred during the infusion as late as 1 year after treatment initiation.</p><p>&nbsp;</p><p>In clinical studies, 59 of 125 (47%) sebelipase alfa-treated patients, including 13 of 19 (68%) infants and 46 of 106 (43%) children and adults, experienced at least 1 hypersensitivity reaction (selected using a validated, pre-determined set of terms grouped together to identify potential hypersensitivity reactions). Signs and symptoms either consistent with or that may be related to a hypersensitivity reaction occurring in two or more patients included but were not limited to abdominal pain, agitation, bronchospasm, chills, diarrhoea, eyelid oedema, eczema, face oedema, hypertension, irritability, laryngeal oedema, lip swelling, nausea, oedema, pallor, pruritus, pyrexia/body temperature increased, rash, tachycardia, urticaria, and vomiting. The majority of reactions occurred during or within 4 hours of the completion of the infusion.</p><p>&nbsp;</p><p><em>Transient hyperlipidaemia </em></p><p>Consistent with its known mechanism of action, asymptomatic increases in circulating cholesterol and triglycerides have been observed following initiation of treatment. These increases have generally occurred within the first 2 to 4 weeks and improved within a further 8 weeks of treatment. See&nbsp;&nbsp; section 5.1.</p><p>&nbsp;</p><p><em>Immunogenicity </em></p><p>There is potential for immunogenicity (see section 4.4). Patients have developed anti-drug antibodies (ADA) to sebelipase alfa.&nbsp; Compared to children and&nbsp; adults, an increased occurrence of ADA positivity was observed within the infant population (10/19 patients).</p><p>&nbsp;</p><p>Among 125 patients with LAL Deficiency enrolled in the clinical&nbsp; studies, 19/125 (15.0%) patients tested positive for anti-drug antibodies (ADAs) at some timepoint after starting treatment with sebelipase alfa (9 children and adult patients and 10 infants). For children and adult patients with LAL Deficiency, ADA positivity was transient with generally low titers of ADAs reported. Persistence of ADA positivity was observed for all 10 infants and persistence of high titer ADAs was observed for 3 of the 10 infants<em>. </em>Among those 19 patients, 11 (58%) also showed the presence of inhibitory antibody activity (NAbs) at some postbaseline timepoint.</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u> <strong><u>Saudi Arabia:</u> </strong></p><p>&bull; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp; Fax: +966-11-205-7662</p><p>-&nbsp; SFDA Call Center: 19999</p><p>-&nbsp; E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>-&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Other GCC States:</u> </strong></p><p>&nbsp;</p><p>&minus; Please contact the relevant competent authority.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, doses of sebelipase alfa were explored up to 7.5 mg/kg once weekly and no specific signs or symptoms were identified following the higher doses. For management of adverse reactions, see sections 4.4 and 4.8.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other alimentary tract and metabolism products, Enzymes; ATC code: A16AB14</p><p>&nbsp;</p><p>Lysosomal acid lipase (LAL) deficiency</p><p>&nbsp;</p><p>LAL deficiency is a rare disease associated with significant morbidity and mortality, which affects individuals from infancy through adulthood. LAL deficiency presenting in infants is a medical emergency with rapid disease progression over a period of weeks that is typically fatal within the first 6 months of life. LAL deficiency is an autosomal recessive lysosomal storage disorder characterised by a genetic defect resulting in&nbsp; a marked decrease or loss in activity of the lysosomal acid&nbsp; lipase (LAL) enzyme.</p><p>&nbsp;</p><p>Deficient LAL enzyme activity results in the lysosomal accumulation of cholesteryl esters and triglycerides in a variety of cell populations, organs and organ systems, among them hepatocytes and macrophages. In the liver, this accumulation leads to hepatomegaly, increased hepatic fat content, transaminase elevation signaling chronic liver injury, and progression to fibrosis, cirrhosis, and complications of end-stage liver disease. In the spleen, LAL deficiency results in splenomegaly, anaemia, and thrombocytopenia. Lipid accumulation in the intestinal wall leads to malabsorption and growth failure. Dyslipidaemia is common, with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides and low high-density lipoprotein cholesterol (HDL-C), associated with increase liver fat content and transaminase elevations. In addition to liver disease, patients with LAL deficiency experience increased risk for cardiovascular disease and accelerated atherosclerosis.</p><p>&nbsp;</p><p>Mechanism of action</p><p>&nbsp;</p><p>Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL).</p><p>&nbsp;</p><p>Sebelipase alfa binds to cell surface receptors via glycans expressed on the protein and is subsequently internalised into lysosomes. Sebelipase alfa catalyses the lysosomal hydrolysis of cholesteryl esters and triglycerides to free cholesterol, glycerol and free fatty acids. Replacement of LAL enzyme activity leads to reductions in liver fat content and transaminases, and enables metabolism of cholesteryl esters and triglycerides in the lysosome, leading to reductions in LDL-C and non- HDL-C, triglycerides, and increases in HDL-C. Improvement in growth occurs as a result of substrate reduction in the intestine.</p><p>&nbsp;</p><p>Clinical studies</p><p>&nbsp;</p><p><em>Infants presenting with LAL deficiency </em></p><p><em><u>Study LAL-CL03</u></em><em> </em></p><p>LAL-CL03 was a multicentre, open-label, single-arm study of sebelipase alfa in 9 patients under 24 months of age with a confirmed diagnosis&nbsp; of LAL&nbsp; deficiency and growth failure with onset before 6 months of age. Patients also had rapidly progressive liver disease and severe hepatosplenomegaly.</p><p>The median age of patients at the time of initiation of dosing was 3 months (range = 1 to 6 months). The median duration of exposure to sebelipase alfa was 55.6 months per patient (range = 1 day to 60 months). Patients received sebelipase alfa at 0.35 mg/kg once weekly (qw) for the first 2 weeks and then 1 mg/kg once weekly. Based on clinical response, dose escalation to 3 mg/kg once weekly occurred as early as 1 month and up to 20 months after starting treatment at 1 mg/kg qw for 6 patients. Two of these 6 patients were subsequently dose escalated to 5 mg/kg once weekly, as allowed by the study protocol.</p><p>&nbsp;</p><p>Efficacy was assessed by comparing the survival experience of sebelipase alfa-treated patients who survived past 12 months of age in Study LAL-CL03 with a historical cohort of untreated infants presenting with LAL deficiency with similar clinical characteristics. In LAL-CL03, 6 of 9 sebelipase alfa-treated infants survived beyond 12 months (67% 12-month survival, 95% CI: 30% to 93%). With continued treatment until 48 months of age, 1 additional patient died&nbsp; at&nbsp; age 15 months. In the historical cohort, 0 of 21 patients survived beyond 8 months of age (0% 12-month survival, 95% CI: 0% to 16%).</p><p>&nbsp;</p><p>Sebelipase alfa resulted in improvements in alanine aminotransferase (ALT) / aspartate aminotransferase (AST) levels (indicating a decrease in&nbsp; liver&nbsp; injury)&nbsp; and&nbsp; in&nbsp; weight gain; improvements were noted within the first several weeks of treatment and were maintained through the end of the study. From baseline to Week 240 (Month 60), the mean reductions for ALT and AST were -43.5 U/l and -45.25 U/l, respectively. From baseline to Week 240, mean weight-for-age percentile improved from 12.74% to 43.17% and mean serum albumin levels increased from 26.9 g/l to 31.98 g/l. Dose escalation to 3 mg/kg once weekly was associated with additional improvements in weight gain, lymphadenopathy and serum albumin.</p><p>&nbsp;</p><p><em><u>Study LAL-CL08</u></em><em> </em></p><p><em>&nbsp;</em></p><p>Study LAL-CL08 was a multicentre, open-label study of sebelipase alfa in 10 infants &le; 8 months of age with confirmed diagnosis of rapidly progressive LAL deficiency requiring urgent intervention, including but not restricted to marked abdominal distension and hepatomegaly, failure to thrive, disturbance of coagulation, severe anaemia, and/or a sibling with a rapidly progressive course of LAL deficiency.</p><p>&nbsp;</p><p>The median age of the study patients on the date of their first infusion of sebelipase alfa was 3 months (range: 0.5 to 4 months). Eight (80%) patients completed the study. The median duration of exposure was 34 months (range: 1 to 37 months). Two (20%) patients were considered early terminated due to death. All 10 patients received a starting dose of 1 mg/kg qw. The 9 patients who survived beyond Week 4 each received a dose escalation to 3 mg/kg qw, and 7 of these patients received a subsequent dose escalation to 5 mg/kg qw, as allowed per study protocol. One patient received a further dose escalation to 7.5 mg/kg qw. Two patients had a subsequent dose reduction, which occurred after successful transplant procedures; one patient received a BMT and the other patient received a HSCT. The percentages (95% confidence intervals [CIs]) of patients surviving to 12, 18, 24, and 36 months of age were 90% (55.5%, 99.7%), 80% (44.4%, 97.5%), 80% (44.4%, 97.5%), and 75% (34.9%, 96.8%), respectively. Two patients were &lt; 36 months of age at the time of study completion and were excluded from the analysis for survival to 36 months. Reductions in AST, gamma glutamyltransferase (GGT), and total bilirubin and increases in serum albumin were observed in the overall study population, with median changes from baseline to last assessment of -34.5 U/L, -66.67 IU/L, -63.64 &mu;mol/L, and 33.33 g/L, respectively.</p><p>&nbsp;</p><p>Height and weight increased gradually. Median changes from baseline in Z-scores for weight for height (WFH) were decreases through Week 4. Starting from Week 24, there were consistent improvements. At Week 144, the median change (range) in Z-scores for WFH was 3.07 (-1.0, 5.3) from baseline.</p><p>&nbsp;</p><p><em>Children and adults with LAL deficiency </em></p><p><em><u>Study LAL-CL02</u></em><em> </em></p><p>Study LAL-CL02 was a multicentre, double-blind, placebo-controlled study in 66 children and adults with LAL deficiency. Patients were randomised to receive sebelipase alfa at a dose of 1 mg/kg (n = 36) or placebo (n = 30) once every other week (qow) for 20 weeks in the double-blind period.</p><p>The mean age range at randomisation was 16.5 years, range 4-58 years (36% were &lt; 12 years old and</p><p>71% were &lt; 18 years old). For study entry, patients were required to have ALT levels of 1.5 X upper limit of normal (ULN). The majority&nbsp; of patients (58%) had LDL-cholesterol &gt; 190 mg/dl at study entry, and 24% of patients with LDL-cholesterol &gt; 190 mg/dl were on lipid lowering medicinal products. Of the 32 patients who had a liver biopsy at study entry, 100% had fibrosis and 31% had cirrhosis. The age range of patients with biopsy evidence of cirrhosis was 4-21 years.</p><p>&nbsp;</p><p>The following endpoints were assessed: normalisation of ALT, decrease in LDL-cholesterol, decrease in&nbsp; non-HDL-cholesterol, normalisation of AST, decrease in triglycerides, increase in HDL- cholesterol, decrease in liver fat content assessed by multi-echo gradient echo magnetic resonance imaging (MEGE-MRI), and improvement in hepatic steatosis measured by morphometry.</p><p>&nbsp;</p><p>A statistically significant improvement in multiple endpoints was observed in the sebelipase alfa- treated group as compared to the placebo group at the completion of the 20-week double-blind period of the study, as shown in Table 3. The absolute reduction in mean ALT level was -57.9 U/l (-53%) in the sebelipase alfa-treated group and -6.7 U/l (-6%) in the placebo group.</p><p>&nbsp;</p><p>Table 3: Primary and secondary efficacy endpoints in LAL-CL02</p><table border="0" cellspacing="0" cellpadding="0" style="width:593px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sebelipase alfa </strong>&nbsp;<strong>(n = 36) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo </strong>&nbsp;<strong>(n = 30) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>P-value<sub>d </sub></strong><sub>&nbsp;</sub></p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary Endpoint </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Normalisation of ALTa&nbsp;</p></td><td style="vertical-align:top"><p>31%&nbsp;</p></td><td style="vertical-align:top"><p>7%&nbsp;</p></td><td style="vertical-align:top"><p>0.0271&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Secondary Endpoints </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>LDL-cholesterol, mean % change from baseline&nbsp;</p></td><td style="vertical-align:top"><p>-28%&nbsp;</p></td><td style="vertical-align:top"><p>-6%&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.0001&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Non-HDL-cholesterol, mean % change from baseline&nbsp;</p></td><td style="vertical-align:top"><p>-28%&nbsp;</p></td><td style="vertical-align:top"><p>-7%&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.0001&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Normalisation of ASTb&nbsp;</p></td><td style="vertical-align:top"><p>42%&nbsp;</p></td><td style="vertical-align:top"><p>3%&nbsp;</p></td><td style="vertical-align:top"><p>0.0003&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides, mean % change from baseline&nbsp;</p></td><td style="vertical-align:top"><p>-25%&nbsp;</p></td><td style="vertical-align:top"><p>-11%&nbsp;</p></td><td style="vertical-align:top"><p>0.0375&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HDL-cholesterol, mean % change from baseline&nbsp;</p></td><td style="vertical-align:top"><p>20%&nbsp;</p></td><td style="vertical-align:top"><p>-0.3%&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.0001&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Liver fat content <sub>c</sub>, mean % change from baseline&nbsp;</p></td><td style="vertical-align:top"><p>-32%&nbsp;</p></td><td style="vertical-align:top"><p>-4%&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 0.0001&nbsp;</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Proportion of patients who achieved normalisation defined as 34 or 43 U/l, depending on age and gender.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Proportion of patients who achieved normalisation defined as 34-59 U/l, depending on age and gender. Evaluated in patients with abnormal baseline values (n = 36 for sebelipase alfa; n = 29 for placebo).</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Evaluated in patients with MEGE-MRI assessments performed (n = 32 for sebelipase alfa; n = 25 for placebo). <sup>d </sup>P-values are from Fisher&rsquo;s exact test for normalisation endpoints and Wilcoxon rank-sum test for all other endpoints.</p><p>&nbsp;</p><p>Paired liver biopsies&nbsp; at baseline&nbsp; and week 20 were available&nbsp; in&nbsp; a subset of patients (n = 26). Of patients with paired liver biopsies, 63% (10/16) of sebelipase alfa-treated patients had improvement in hepatic steatosis (at least  5% reduction) as measured by morphometry compared to 40% (4/10) of placebo patients. This difference was not statistically significant.</p><p>&nbsp;</p><p><em>Open-label period </em></p><p>Patients who participated in Study LAL-CL02 were eligible to continue treatment in an open-label periods of the study. 66 patients entered the first open-label period (up to 130 weeks) at a sebelipase alfa dose of 1 mg/kg once every other week. In patients who had received sebelipase alfa during the double-blind period, reductions in ALT levels during the first 20 weeks of treatment were maintained and further improvements were seen in lipid parameters including LDL-cholesterol and</p><p>HDL-cholesterol levels. Twelve (12) of 66 patients in the open label period were dose escalated to 3 mg/kg once every other week based on clinical response.</p><p>&nbsp;</p><p>Placebo patients had persistently elevated serum transaminase and abnormal serum lipid levels during the double-blind period. Consistent with what was observed in sebelipase alfa-treated patients during the double-blind period, initiation of treatment with sebelipase alfa during the open-label period produced rapid improvements in ALT levels and in lipid parameters including LDL-cholesterol and HDL-cholesterol levels.</p><p>&nbsp;</p><p>Improvements in ALT levels and in lipid parameters (LDL-cholesterol and HDL-cholesterol levels) were maintained during the open-label expanded treatment period for up to 256 weeks (5 years), with overall mean treatment duration of 42.5 months.</p><p><em>Study LAL-CL01/LAL-CL04</em><em> </em></p><p><em>&nbsp;</em></p><p>In a separate open-label study (LAL-CL01/LAL-CL04) in adult patients with LAL deficiency, improvements in serum transaminase and lipid levels were sustained through the 260-week treatment period. Eight of nine patients transitioned from Study LAL-CL01 after 4 weeks of treatment (0.35 mg/kg qw, 1 mg/kg qw, or 3 mg/kg qw) to Study LAL-CL04 (1 mg/kg qow or 3 mg/kg qow), with 5 patients receiving a dose of 1 mg/kg qow and 3 patients receiving a dose of 3 mg/kg qow. Increases in serum transaminases and LDL-cholesterol and decreases in HDL-cholesterol were observed during the period in which patients were off treatment with sebelipase alfa.</p><p>&nbsp;</p><p><em>Study LAL-CL06</em><em> </em></p><p><em>&nbsp;</em></p><p>LAL-CL06 was a multicenter, open-label study in 31 children and adults with LAL deficiency and was designed to include patients who may have been ineligible&nbsp; for previous clinical studies due to age, disease progression, previous treatment by haematopoietic stem cell or liver transplantation, less common disease manifestations, or disease characteristics that precluded participation in a placebo- controlled study. At least 4 patients in the study were to be between the age of 2 and 4 years. The study consisted of a screening period of up to 45 days, a treatment period of up to 96 weeks and an expanded treatment period of up to 48 weeks (for a total of up to 144 weeks of treatment). The median duration of exposure to sebelipase alfa was 33 months (range: 14 to 33.5 months).</p><p>&nbsp;</p><p>Twenty-eight of the 31 patients completed the 96-week treatment period (1 patient discontinued treatment at week 61 due to withdrawal of consent, 1 patient at week 64 due to pregnancy and 1 patient at week 76 due to transition to commercial therapy). Twenty-five of the 28 patients who completed the 96-week treatment period continued to receive treatment with sebelipase alfa during the extended treatment period. All 31 patients received sebelipase alfa at a starting dose of 1 mg/kg qow. Thirteen of the 31 patients received dose escalations as allowed by the study protocol. Eleven of these 13 patients had an initial&nbsp; dose escalation from 1 mg/kg qow to 3 mg/kg qow, and 4 of these patients had a further dose escalation to 3 mg/kg qw.</p><p>&nbsp;</p><p>Serum transaminases (ALT/AST) were elevated at baseline in approximately 75% of patients, and approximately half of the patients had levels &gt; 1.5 x ULN. Reductions in ALT&nbsp; and AST were evident by week 4 and were sustained during long-term treatment with sebelipase alfa, with mean changes from baseline to week 144 of -40.3 U/L (-32.0%) and -42.2 U/L (34.2%), respectively.</p><p>&nbsp;</p><p>Transient increases in total cholesterol, non-HDL-C, and LDL-C were observed shortly after initiation of treatment (week 4), and then levels dropped to below baseline by the next assessment at week 8. This observation is consistent with mobilization of accumulated lipid substrates from the affected tissues and has been observed in previous clinical studies of sebelipase alfa. Continued long-term therapy with sebelipase alfa produced an improvement in the serum lipid profile, with mean changes from baseline to week 144 in LDL-C, triglycerides, and non-HDL-C of -54.2 mg/dL, -47.5 mg/dL, and -63.7 mg/dL, respectively, and mean percent changes of -31.2%, -19.1%, and -30.3%, respectively. An increase in HDL-C levels was observed, with a mean increase from baseline to week 144 of 10.2 mg/dL and a mean percent increase of 39.7%.</p><p>&nbsp;</p><p><em>Liver biopsy data in children and adult population</em><em> </em></p><p>Liver biopsy is the accepted standard for histologic assessment of liver disease activity and fibrosis, despite such limitations as sampling variability, potential complications of an invasive technique, and subjective scoring.</p><p>&nbsp;</p><p>Liver biopsies from 59 patients enrolled in Studies LAL-CL02 and LAL-CL06 were assessed by an independent pathologist at a central facility, who was blinded to assessment timepoint and treatment assignment. All biopsies were evaluated semi-quantitatively for histologic features such as Ishak Fibrosis Score, portal inflammation, lobular inflammation, macrovesicular steatosis, and microvesicular steatosis. Computer-assisted morphometry was used to quantify percent steatosis, fibrogenic cells, collagen, and macrophages.</p><p>&nbsp;</p><p>Liver biopsies were evaluable for Ishak Fibrosis Scores for 59 patients at baseline and 38 patients at Month 12 (meaning after 12 months of exposure to sebelipase alfa). There were 36 patients who had Ishak scores at both baseline and Month 12.</p><p>&nbsp;</p><p>At baseline, 3 of 59 patients (5%) had Ishak scores of 0 (no fibrosis) and 15 (25%) patients had Ishak scores of 6, indicating established or advanced cirrhosis. Ishak scores improved by Month 12, when 9 of 38 patients (24%) had Ishak scores of 0 and 7 patients (18%) had Ishak scores of 6. Overall, 31 of 36 patients (86.1%) had Ishak scores that had improved or did not progress at Month 12. There were</p><p>10 patients (28%) with a &ge; 2 point reduction in Ishak scores from baseline to Month 12, including changes from stage 2 to stage 0, from stage 3 to stages 1 and 0, from stage 5 to stage 0 (&gt; 3-point reduction), and from stage 6 to stages 4 and 3. Globally, these 10 patients&nbsp; with a &ge; 2-point reduction in Ishak stage scores had also substantial improvements in other study-related assessments, such as reduction in ALT, LDL-C, HDL-C, and non-HDL-C over the same time period.</p><p>&nbsp;</p><p>Based on eligibility criteria, patients in Study LAL-CL06&nbsp; generally&nbsp; were expected to have more cirrhosis and intractable disease than patients in Study LAL-CL02, due to more advanced liver disease at baseline. The liver biopsy findings in Studies LAL-CL02 and LAL-CL06 were consistent with each other. At baseline, in both studies, the majority&nbsp; of patients had microvesicular steatosis (57 of 59, 97%), including 45 of 59 patients (76%) with a score 4 (scale of 0-4, with severe is defined as 4 and equivalent to &gt; 66% hepatocyte involvement/replacement), as expected with the underlying disease. At month 12, the percentage of patients with severe microvesicular steatosis were decreased, with 17 of 38 patients (45%) having &gt; 66% hepatocyte involvement/replacement (score 4).</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p>Eighty-eight of 125 patients (70%) who received sebelipase alfa during clinical studies were in the paediatric and adolescent age range (1 month up to 18 years) at the time of first dose. Currently available data are described sections 4.8 and 5.1.</p><p>&nbsp;</p><p>LAL deficiency registry</p><p>&nbsp;</p><p>Medical or healthcare professionals are encouraged to participate and enrol all patients diagnosed with LAL deficiency in the LAL deficiency registry.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of sebelipase alfa in children and adults were determined using a population pharmacokinetic analysis of 102 patients with LAL deficiency who received intravenous infusions of sebelipase alfa across 4 clinical studies LAL-CL02, LAL-CL03, LAL-CL04 and LAL-CL06 (Table 4).</p><p>Predicted pharmacokinetic and exposure parameters of sebelipase alfa from clinical trials are presented by age group in Table 4.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 4: Mean (SD) Predicted Pharmacokinetic and Exposure Parameters following Repeated Administration of 1 mg/kg Sebelipase Alfa in Patients With LAL Deficiency by Age Group</p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:618px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Parameter </strong></p></td><td style="vertical-align:top"><p><strong>Age &lt; 4 years (N = 5) </strong></p></td><td style="vertical-align:top"><p><strong>Age 4 to &lt; 12 years (N = 32) </strong></p></td><td style="vertical-align:top"><p><strong>Age 12 to &lt; 18 years (N=34) </strong></p></td><td style="vertical-align:top"><p><strong>&ge; 18 years (N = 31) </strong></p></td></tr><tr><td style="vertical-align:top"><p>CL (L/h)</p></td><td style="vertical-align:top"><p>17.2 (7.07)</p></td><td style="vertical-align:top"><p>22.8 (11.2)</p></td><td style="vertical-align:top"><p>32.7 (10.8)</p></td><td style="vertical-align:top"><p>37.6 (13.8)</p></td></tr><tr><td style="vertical-align:top"><p>Q (L/h)</p></td><td style="vertical-align:top"><p>1.96 (0.963)</p></td><td style="vertical-align:top"><p>1.41 (0.633)</p></td><td style="vertical-align:top"><p>1.61 (0.551)</p></td><td style="vertical-align:top"><p>1.54 (0.594)</p></td></tr><tr><td style="vertical-align:top"><p>Vc (L)</p></td><td style="vertical-align:top"><p>2.06 (1.22)</p></td><td style="vertical-align:top"><p>2.72 (1.43)</p></td><td style="vertical-align:top"><p>4.06 (2.01)</p></td><td style="vertical-align:top"><p>6.01 (5.43)</p></td></tr><tr><td style="vertical-align:top"><p>Vss (L)</p></td><td style="vertical-align:top"><p>6.13 (1.22)</p></td><td style="vertical-align:top"><p>6.79 (1.43)</p></td><td style="vertical-align:top"><p>8.13 (2.01)</p></td><td style="vertical-align:top"><p>10.1 (5.43)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>&frac12;&beta; </sub>(h)</p></td><td style="vertical-align:top"><p>1.88 (0.69)</p></td><td style="vertical-align:top"><p>2.71 (1.63)</p></td><td style="vertical-align:top"><p>2.18 (1.28)</p></td><td style="vertical-align:top"><p>2.24 (1.05)</p></td></tr><tr><td style="vertical-align:top"><p>AUCss</p><p>(ng &times; h/mL)</p></td><td style="vertical-align:top"><p>521 (174)</p></td><td style="vertical-align:top"><p>1410 (774)</p></td><td style="vertical-align:top"><p>1610 (658)</p></td><td style="vertical-align:top"><p>2060 (793)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax,ss (ng/mL)</p></td><td style="vertical-align:top"><p>247 (80.6)</p></td><td style="vertical-align:top"><p>679 (370)</p></td><td style="vertical-align:top"><p>786 (315)</p></td><td style="vertical-align:top"><p>997 (367)</p></td></tr></tbody></table><p>Note: Estimates are derived from data from Studies LAL-CL02, LAL-CL03, LAL-CL04, and LAL-CL06. AUC<sub>ss </sub>= area under the serum concentration-time curve at steady state; CL= clearance; C<sub>max,ss </sub>= maximum observed serum concentration under steady state conditions; PK = pharmacokinetic(s); Q = peripheral clearance; t<sub>&frac12;&beta; </sub>= terminal elimination half-life; Vc = central volume of distribution; Vss = Volume of distribution at steady state</p><p>&nbsp;</p><p>Linearity/non-linearity</p><p>&nbsp;</p><p>No conclusion on the linearity of sebelipase alfa pharmacokinetics can be made due to limited data at higher exposures. No drug accumulation is observed following 1 mg/kg or 3 mg/kg once every other week dosing, although observations for the drug accumulation at 3mg/kg every other week are based on a limited&nbsp; number of patients. Accumulation following once weekly dosing is&nbsp; not expected based on relatively rapid drug clearance.</p><p>&nbsp;</p><p>Special populations</p><p>&nbsp;</p><p>During the covariate analysis of the population pharmacokinetics model for sebelipase alfa, age, sex and enzyme maturation were found to not have a significant influence on CL (drug clearance) and V<sub>c </sub>(central volume of distribution) of sebelipase alfa. Body weight and body surface area are significant covariates on CL. Sebelipase alfa has not been investigated in patients aged 65 years or older.</p><p>&nbsp;</p><p>There is limited information on sebelipase alfa pharmacokinetics in non-Caucasian ethnic groups.</p><p>&nbsp;</p><p>Sebelipase alfa is a protein and is expected to be metabolically degraded through peptide hydrolysis. Consequently, impaired liver function is not expected to affect the pharmacokinetics of sebelipase alfa. There is a lack of data in patients with severe hepatic impairment.</p><p>&nbsp;</p><p>Renal elimination of sebelipase alfa is considered a minor pathway for clearance. There is a lack of data in patients with renal impairment.</p><p>&nbsp;</p><p>Immunogenicity</p><p>&nbsp;</p><p>As with all therapeutic proteins, there is the potential for the development of immunogenicity (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity in rats and monkeys, or fertility, embryo-foetal and peri- and postnatal development in rats and rabbits. Chronic toxicity studies in juvenile cynomolgous monkeys showed no toxicity at doses up to 3 times the recommended dose in infants and 10 times the recommended dose in adults/children. No adverse findings were observed in rat and rabbit embryofoetal development studies at doses up to at least 10 times the adult/children recommended dose and in rat fertility and peri- postnatal development studies at doses up to 10 times the adult/children recommended dose.</p><p>&nbsp;</p><p>Studies to evaluate the mutagenic and carcinogenic potential of sebelipase alfa have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium citrate</p><p>Citric acid monohydrate</p><p>Human serum albumin</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials: 2 years. 
 
After dilution: Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2°C to 8°C, or up to 12 hours below 25 °C. 
 
From a microbiological point of view, the diluted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, or up to 12 hours below 25 °C, unless dilution has taken place in controlled and validated aseptic conditions. 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clear glass vial (Type I) with a siliconised butyl rubber stopper, and an aluminium seal with a plastic flip-off cap, containing 10 ml of concentrate.</p><p>&nbsp;</p><p>Pack size: 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial of KANUMA is intended for single use only. KANUMA has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion using aseptic technique.</p><p>The diluted solution should be administered to patients using a low-protein binding infusion&nbsp; set equipped with an in-line, low-protein binding 0.2 &mu;m filter, with a surface area of greater than 4.5 cm<sup>2 </sup>as available in order to avoid filter occlusion.</p><p>&nbsp;</p><p>Preparation of the sebelipase alfa infusion</p><p>&nbsp;</p><p>KANUMA should be prepared and used according to the following steps. Aseptic technique should be used.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The number of vials to be diluted for infusion should be determined based on the patient&rsquo;s weight and prescribed dose.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is recommended to allow KANUMA vials to reach a temperature between 15 &deg;C and 25 &deg;C prior to dilution to minimise the potential for the formation of sebelipase alfa protein&nbsp; particles in solution. The vials should not be left outside the refrigerator longer than 24 hours prior to dilution for infusion. The vials should not be frozen, heated or microwaved and should be protected from light.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The vials should not be shaken. Prior to dilution,&nbsp; the concentrate in the vials&nbsp; should be inspected visually; the concentrate should be clear to slightly opalescent, colourless to slightly coloured (yellow). Due to the proteinaceous nature of the medicinal product, slight flocculation (e.g., thin translucent fibres) may be present in the vial concentrate and is acceptable for use.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use if the concentrate is cloudy, or if foreign particulate matter is present.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Up to 10 ml of concentrate should be slowly withdrawn from each vial and diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion. See Table 5 for recommended total infusion volumes by weight range. The solution should be mixed gently, and not be shaken.</p><p>&nbsp;</p><p>Table 5: Recommended infusion volumes*</p><table border="0" cellspacing="0" cellpadding="0" style="width:602px"><tbody><tr><td style="vertical-align:top"><p><strong>Weight range (kg) </strong></p></td><td style="vertical-align:top"><p><strong>1 mg/kg dose </strong></p></td><td style="vertical-align:top"><p><strong>3 mg/kg dose </strong></p></td><td style="vertical-align:top"><p><strong>5 mg/kg dose** </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Total infusion volume (ml) </strong></p></td><td style="vertical-align:top"><p><strong>Total Infusion Volume (mL) </strong></p></td><td style="vertical-align:top"><p><strong>Total Infusion Volume (mL) </strong></p></td></tr><tr><td style="vertical-align:top"><p>1-10</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>11-24</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>150</p></td></tr><tr><td style="vertical-align:top"><p>25-49</p></td><td style="vertical-align:top"><p>50</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>250</p></td></tr><tr><td style="vertical-align:top"><p>50-99</p></td><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td></tr><tr><td style="vertical-align:top"><p>100-120</p></td><td style="vertical-align:top"><p>250</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>600</p></td></tr></tbody></table><p>* The infusion volume should be based on the prescribed dose and should be prepared to a final sebelipase alfa concentration of 0.1-1.5 mg/ml.</p><p>** For patients with LAL Deficiency presenting within the first 6 months of life who do not achieve an optimal clinical response with a dose of 3 mg/kg.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alexion Europe SAS 
103-105 rue Anatole France 
92300 Levallois-Perret 
France 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>